Using spectral-domain optical coherence tomography (OCT) to observe the morphology and epithelial thickness (ET) of the palisades of Vogt (POV), and to evaluate the role of age and region on these structures.One hundred twelve eyes of 112 healthy subjects were enrolled and divided into 4 groups: A (0–19), B (20–39), C (40–59), and D (≥60 years old). RTvue-100 OCT was applied on the cornea and the limbus. The morphology of the subepithelial stroma underneath the epithelium of POV was classified into typical and atypical types. Maximum ET of POV was measured manually from OCT images.The positive rate of typical POV in superior, nasal, temporal, and inferior limbus was: Group A: 100%, 69.2%, 65.4%, 100%; Group B: 100%, 73.5%, 61.8%, 94.1%; Group C: 95.8%, 41.7%, 37.5%, 83.3%; Group D: 67.9%, 0%, 3.6%, 25%, showing a significant decreasing tendency with age. The maximum ET of POV in superior, nasal, temporal, and inferior limbus was: Group A: 103.5 ± 10.1 um, 89.2 ± 9.7 um, 87.9 ± 13.6 um, 104.7 ± 14.1 um; Group B: 111.4 ± 15.8 um, 85.3 ± 9.9 um, 88.2 ± 8.6 um, 112.6 ± 19.7 um; Group C: 116.4 ± 16.4 um, 82.8 ± 11.6 um, 87.0 ± 11.6 um, 120.0 ± 25.6 um; Group D: 96.3 ± 17.9 um, 73.8 ± 15.9 um, 79.2 ± 16.7 um, 87.4 ± 18.5 um. Age-dependent change was observed. In general, the maximum ET of POV in superior/inferior quadrants was thicker than the other 2 quadrants.Spectral-domain OCT is a useful tool to observe the limbal microstructure and provide invaluable information. Aging and anatomic regions had significant effects on the microstructure of these areas.
Importance: The clinical implications of different morphologies of choroidal neovascularization (CNV), as evaluated by ocular coherence tomography angiography (OCTA) in neovascular age-related macular degeneration (nAMD), are lacking. Background: To describe the morphology of CNV in nAMD using OCTA, and to compare the visual prognosis and other structural OCT biomarkers between different morphologic patterns. Design: Retrospective cohort study. Participants: One hundred and forty eyes with nAMD treated with anti-vascular endothelial growth factor (VEGF). Methods: Patients were examined using OCTA prior to and at 3, 6 and 12 months after receiving anti-VEGF therapy. Main Outcome Measures: Best-corrected visual acuity (BCVA) and morphologic retinal features. Results: Organized CNV was identified in 110/140 eyes (78.6%) using OCTA. These CNV complexes could be divided into three OCTA patterns: the 'medusa' pattern (n = 41), characterized by branching vessels radiating in all directions; the 'seafan' pattern (n = 43), characterized by branching vessels radiating to one side of the lesion; and the 'tangled' pattern (n = 26), characterized by globular entwined vessels without a main trunk. At baseline, the eyes with the tangled pattern were from younger patients (P = .031) with better BCVA (P = .007). There were also fewer intraretinal cysts (P = .021), less fibrovascular pigment epithelial detachment (P = .009), and more pachychoroid (P = .007) in eyes with the tangled pattern on OCT. At 12 months post-treatment, patients with the tangled CNV pattern also showed greater visual improvement than patients with the other two patterns (P = .049).
Purpose: To study the early changes of vitreomacular microstructure by optical coherence tomography (OCT) after intravitreal gas injection for the treatment of idiopathic impending or early full-thickness macular hole (FTMH). Methods: A retrospective, interventional case series. Results: A total of 21 eyes were included. In the impending macular hole, 8/8 achieved vitreomacular traction (VMT) release, while a macular hole developed in 1 case. On postoperative day 1, the vitreomacular configuration by OCT showed either a flattening (n = 3) or elevation (n = 1) pattern. In early FTMH, vitreomacular separation was achieved in 10/13 cases, but macular hole closure was only observed in 3 cases. On postoperative day 1, only flattening of the vitreomacular configuration was observed (n = 5). Enlargement of the macular hole was found in 4 cases. Conclusions: VMT separation can be achieved with intravitreal gas injection by mechanically stretching the posterior vitreous cortex, causing either flattening or steepening of the vitreomacular configuration. However, it did not always result in macular hole closure.
Optic neuritis, inflammation of the optic nerve, can cause visual impairment through retinal nerve fiber layer (RNFL) degeneration. Optical coherence tomography could serve as a sensitive noninvasive tool for measuring RNFL thickness and evaluating the neuroprotective effects of treatment. We conducted a meta-analysis to compare RNFL loss between novel add-on treatments and corticosteroid therapy at least 3 months after acute optic neuritis. The outcome measures were mean differences (MDs) in (1) RNFL thickness compared with the baseline in the affected and unaffected eye and (2) LogMAR visual acuity (VA). Seven studies involving five novel agents (memantine, erythropoietin, interferon-beta, phenytoin, and clemastine) were analyzed. When compared with the baseline RNFL thickness of the affected eye, the neuroprotective effects of novel add-on treatments could not be demonstrated. The difference in visual outcomes was also not significant between the two treatment groups. One study revealed that phenytoin has the potential to alleviate RNFL loss when the baseline thickness of the unaffected eye is considered. Larger randomized controlled trials with suitable outcome measures are warranted to evaluate the neuroprotective effects of novel treatments. Further studies should also tailor therapies to specific patient populations and investigate a more targeted treatment for acute optic neuritis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.